New preclinical work in multiple myeloma ties bortezomib resistance to metabolic rewiring driven by bone marrow stromal cells through interleukin-6 signaling. Using co-culture metabolomics and isotope tracing, the study reports a convergent metabolic program that supports resistance, with patient proteomics linking IL-6 abundance to metabolic pathway expression associated with mitochondria, glycolysis, serine and nucleotide metabolism.